siRNA drug delivery across the blood–brain barrier in Alzheimer's disease
Advanced Drug Delivery Reviews · 2023-08 · 199 · 114968
DOI: 10.1016/j.addr.2023.114968 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2023-08. Verfasst von Muhammad Imran Sajid und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Pharmaceutical Sciences, Harry and Diane Rinker Health Science Campus, Chapman University School of Pharmacy, Irvine, CA…. Hauptthemen laut MEDLINE: Alzheimer Disease, Neurodegenerative Diseases. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 273 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NHLBI NIH HHS, NIAID NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is a progressive neurodegenerative disease with a few FDA-approved drugs that provide modest symptomatic benefits and only two FDA-approved disease-modifying treatments for AD. The advancements in understanding the causative genes and non-coding sequences at the molecular level of the pathophysiology of AD have resulted in several exciting research papers that employed small interfering RNA (siRNA)-based therapy. Although siRNA is being sought by academia and biopharma industries, several challenges still need to be addressed. We comprehensively report the latest advances in AD pathophysiology, druggable targets, ongoing clinical trials, and the siRNA-based approaches across the blood-brain barrier for addressing AD. This review describes the latest delivery systems employed to address this barrier. Critical insights and future perspectives on siRNA therapy for AD are also provided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical and Pharmaceutical Sciences, Harry and Diane Rinker Health Science Campus, Chapman University School of Pharmacy, Irvine, CA 92618, USA; Faculty of Pharmacy, University of Central Punjab, Lahore…
- Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad 44000, Pakistan.
- Department of Pharmacology, Faculty of Pharmaceutical Sciences, Federal Urdu University of Arts, Science and Technology, Karachi, Pakistan.
- Department of Chemistry and Chemical Engineering, Syed Baber Ali School of Science and Engineering, Lahore University of Management Sciences, 54792 Lahore, Pakistan.
- Department of Biomedical and Pharmaceutical Sciences, Harry and Diane Rinker Health Science Campus, Chapman University School of Pharmacy, Irvine, CA 92618, USA; Department of Neurology, University of California, Irvine…
- Department of Biomedical and Pharmaceutical Sciences, Harry and Diane Rinker Health Science Campus, Chapman University School of Pharmacy, Irvine, CA 92618, USA.
Förderung
- NIA NIH HHS
- NHLBI NIH HHS
- NIAID NIH HHS
- Chapman University
- National Institutes of Health
Zitieren
APA
Imran Sajid, M., Sultan Sheikh, F., Anis, F., Nasim, N., Sumbria, R. K., Nauli, S. M., & Kumar Tiwari, R. (2023). siRNA drug delivery across the blood–brain barrier in Alzheimer's disease. Advanced Drug Delivery Reviews, 199, 114968. https://doi.org/10.1016/j.addr.2023.114968
Vancouver
Imran Sajid M, Sultan Sheikh F, Anis F, Nasim N, Sumbria RK, Nauli SM, et al. siRNA drug delivery across the blood–brain barrier in Alzheimer's disease. Advanced Drug Delivery Reviews. 2023;199:114968. doi:10.1016/j.addr.2023.114968
BibTeX
@article{ImranSajid2023,
author = {Imran Sajid, Muhammad and Sultan Sheikh, Fahad and Anis, Faiza and Nasim, Nourina and Sumbria, Rachita K and Nauli, Surya M and Kumar Tiwari, Rakesh},
title = {siRNA drug delivery across the blood–brain barrier in Alzheimer's disease},
journal = {Advanced Drug Delivery Reviews},
year = {2023},
volume = {199},
pages = {114968},
doi = {10.1016/j.addr.2023.114968}
}
EUVIMED